You can buy or sell DFFN and other stocks, options, ETFs, and crypto commission-free!
Diffusion Pharmaceuticals Inc. Common Stock, also called Diffusion Pharmaceuticals, is a clinical stage company which engages lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, for use in those life threatening conditions in which cellular oxygen deprivation is the basis for significant unmet medical needs. Read More The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
52 Week High
52 Week Low
Research And Development
Stock Price, News, & Analysis for Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pa...
Simply Wall StFeb 16
Does Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Have A High Beta?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first type is company specific...
-$0.90 per share
-$0.06 per share